Endocrine Society Members Participated in FDA Hypoglycemia Workshop

On Sept. 12, Endocrine Society members Rob Lash, MD, and David Aron, MD, took part in a public workshop devoted to hypoglycemia in older adults sponsored by the U.S. Food and Drug Administration (FDA).

Aron was part of a panel that discussed current hypoglycemia medication safety efforts.  Lash, chair of the Society’s Clinical Affairs Core Committee and Hypoglycemia Quality Improvement Project (HQuIP), shared the Society’s efforts to reduce the incidence of hypoglycemia through HQuIP, as well as the various partnerships with a variety of federal agencies to raise the awareness of hypoglycemia.

The free, one-day workshop entitled “Reducing the Risk of Preventable Adverse Drug Events Associated with Hypoglycemia in the Older Population” was hosted by the FDA’s Center for Drug Evaluation and Research, Professional Affairs and Stakeholder Engagement Staff.

The workshop discussed the importance of individualized glycemic control targets for older patients with diabetes to reduce the risk of serious hypoglycemia, identified and discussed medication safety efforts, discussed future areas of research which could be explored to reduce the risk of serious hypoglycemia, and disseminated the results of this discussion to inform patients, patient advocates, and healthcare practitioners.

Look for a more in-depth article on the workshop in the November issue of Endocrine News

Find more in